Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05201066 · ClinicalTrials.gov registry record · Phase 2
Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.
A Phase 2 study of Myelodysplastic Syndromes and Leukemia, Myelomonocytic, Chronic, sponsored by Novartis Pharmaceuticals.
- Active
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
- 20
- Study locations
NCT05201066 is a Phase 2 study of Myelodysplastic Syndromes and Leukemia, Myelomonocytic, Chronic that is active but no longer recruiting, run by Novartis Pharmaceuticals. The registered enrollment target is 33 participants, below the 285-participant average among 173 other Myelodysplastic Syndromes trials with a reported enrollment target (88% lower). The trial reports 20 study locations across 14 states.
The verdict
NCT05201066, a Phase 2 study of Myelodysplastic Syndromes and Leukemia, Myelomonocytic, Chronic, is active but no longer recruiting, sponsored by Novartis Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is intended to collect safety data from participants who completed the parent protocols but are still benefiting from study treatment. The study population consists of participants who tolerate study treatment of the parent studies. Collecting safety information from long-term exposure might offer the unique opportunity to detect rare Adverse Events.
Conditions Studied
Interventions
- DRUG venetoclax
- DRUG azacitidine
- DRUG decitabine
- DRUG spartalizumab
- DRUG sabatolimab
Study Locations (20)
Other
- Novartis Investigative Site - Tianjin
- Novartis Investigative Site - Prague
- Novartis Investigative Site - Toulouse
- Novartis Investigative Site - Alexandroupoli
- Novartis Investigative Site - Pátrai
- Novartis Investigative Site - Fukushima
- Novartis Investigative Site - Kuala Lumpur
Oregon
- Oregon Health Sciences University - Portland
Utah
- Huntsman Cancer Institute Univ of Utah - Salt Lake City
Victoria
- Novartis Investigative Site - Clayton
Santa Catarina
- Novartis Investigative Site - Florianópolis
British Columbia
- Novartis Investigative Site - Vancouver
Jilin
- Novartis Investigative Site - Changchun
Baden-Wurttemberg
- Novartis Investigative Site - Freiburg im Breisgau
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2023-02-13 |
| Est. Completion | 2028-02-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05201066
The ClinicalTrials.gov registry entry for NCT05201066 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 285-participant average among 173 other Myelodysplastic Syndromes trials with a reported enrollment target (88% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Myelodysplastic Syndromes appearing as the primary indexed condition, and to 5 interventions - of which venetoclax is the first listed.
NCT05201066 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Other, Oregon, Utah.
Frequently Asked Questions
What is clinical trial NCT05201066 about?
NCT05201066 is a clinical study titled "Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.". This study is intended to collect safety data from participants who completed the parent protocols but are still benefiting from study treatment. The study population consists of participants who tolerate study treatment of the parent studies. Collecting safety information from long-term exposure mi...
What is the current status of trial NCT05201066?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2023-02-13. Estimated completion is 2028-02-14.
What conditions does trial NCT05201066 study?
This clinical trial studies the following conditions: Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic.
What interventions are being tested in trial NCT05201066?
The interventions under investigation include: venetoclax (DRUG), azacitidine (DRUG), decitabine (DRUG), spartalizumab (DRUG), sabatolimab (DRUG).
Who is sponsoring clinical trial NCT05201066?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05201066 being conducted?
This trial has 20 study locations across Oregon, Utah, Victoria, Santa Catarina, British Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myelodysplastic Syndromes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Pilot, Open-Label Study of Luspatercept for Patients With Lower Risk Myelodysplastic Syndromes (MDS)
RECRUITING · Phase 2
-
Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations
RECRUITING · Phase 2
-
Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms
RECRUITING · Phase 2
-
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
RECRUITING · Phase 2
-
Ascorbate in Myelodysplastic Syndrome
RECRUITING · Phase 2
-
A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.